Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

49143 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ABACAVIR AND LAMIVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ENTECAVIR LAMIVUDINE ORAL ABACAVIR , LAMIVUDINE AND ZIDOVUDINE ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE DOLUTEGRAVIR SODIUM AND LAMIVUDINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE ENTECAVIR ANHYDROUS LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 FOETAL EXPOSURE DURING PREGNANCY 2841
1 PAIN 2230
2 DRUG RESISTANCE 2228
3 DRUG INTERACTION 2193
4 VIROLOGIC FAILURE 2168
5 PATHOGEN RESISTANCE 2035
6 ANXIETY 1975
7 PRODUCT DOSE OMISSION ISSUE 1965
8 PYREXIA 1942
9 NAUSEA 1890
See all common reactions for Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 102 0.7907
1 HIV VIRAEMIA 122 0.5810
2 VIRAL MUTATION IDENTIFIED 1889 0.5123
3 IMMUNE RECONSTITUTION SYNDROME 652 0.5050
4 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 122 0.4388
5 VIROLOGIC FAILURE 2168 0.4027
6 TOTAL LUNG CAPACITY INCREASED 103 0.3787
7 BLOOD HIV RNA INCREASED 595 0.3278
8 HEPATITIS B DNA INCREASED 207 0.3071
9 LIPODYSTROPHY ACQUIRED 652 0.3068
See all enriched reactions for Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]